|
市場調査レポート
商品コード
1401078
髄腔内ポンプの世界市場規模、シェア、産業動向分析レポート:用途別、タイプ別、地域別展望と予測、2023年~2030年Global Intrathecal Pumps Market Size, Share & Industry Trends Analysis Report By Application (Pain, and Spasticity), By Type (Morphine, Ziconotide, Baclofen, Bupivacaine, Clonidine, and Others), By Regional Outlook and Forecast, 2023 - 2030 |
||||||
|
髄腔内ポンプの世界市場規模、シェア、産業動向分析レポート:用途別、タイプ別、地域別展望と予測、2023年~2030年 |
出版日: 2023年12月21日
発行: KBV Research
ページ情報: 英文 198 Pages
納期: 即納可能
![]() |
髄腔内ポンプ市場規模は2030年までに4億9,170万米ドルに達すると予測され、予測期間中のCAGRは5.7%の市場成長率で上昇する見込みです。
さらに、COVID-19パンデミックは市場に中程度の影響を与えました。パンデミックの初期段階では、髄腔内ポンプ植え込みに関するものを含め、多くの選択的手術や医療処置が延期されたり、中止されたりしました。病院やヘルスケア施設は、COVID-19症例を優先するよう強いプレッシャーにさらされ、緊急性のない処置の遅れにつながった。この遅延は市場の成長軌道に影響を及ぼしました。患者は選択的手術を延期し、新規導入と交換の両方に影響を及ぼしたからです。パンデミックによるサプライチェーンの世界の混乱は、医療機器や部品の入手性に影響を与えました。これらのポンプや関連付属品のメーカーは、原材料の調達、生産の遅れ、物流の問題といった課題に直面しました。こうした混乱は市場の変動につながり、供給側と需要側の双方に影響を与えました。その結果、こうした変化により、市場は今後数年間で大きく成長すると予想されます。
しかし、髄腔内ポンプ療法には、ポンプ、外科的植え込み、関連処置の費用など、多額の初期費用がかかるため、経済的な障壁が生じる可能性があります。十分な保険が適用されない患者や経済的に余裕のない患者は、この先進的な治療法を利用するための課題に直面する可能性があります。一貫性のない、または不十分な償還方針は、髄腔内ポンプ療法の普及を妨げる可能性があります。保険償還がない、または保険償還率が治療に関連する費用を十分にカバーしていないため、ヘルスケアプロバイダーが治療選択肢としてこの治療を提供する意欲をなくす可能性があります。患者の経済的負担は、患者のアドヒアランスの低下、髄腔内ポンプ療法に対する消極的な姿勢、あるいは治療中止の可能性につながる可能性があります。以上のような側面から、市場の成長は今後数年間で低下すると予想されます。
用途別展望
用途別に見ると、市場は痙縮と疼痛に細分化されます。痙縮セグメントは、2022年の市場で大きな収益シェアを獲得しました。バクロフェンなどの薬剤を脊髄に直接投与します。バクロフェンは筋弛緩薬で、中枢神経系に作用して痙縮を抑えます。ドラッグデリバリーの標的化により、作用部位における薬剤の濃度がより適切になり、筋緊張と痙縮のより良いコントロールにつながります。髄腔内ポンプ療法によって痙縮をコントロールすることで、筋機能と可動域を改善することができます。これにより、理学療法やリハビリテーションをより効果的に行うことができ、全体的な運動能力や機能性が向上します。
タイプ別展望
タイプ別に見ると、市場はバクロフェン、ブピバカイン、クロニジン、モルヒネ、ジコノタイド、その他に区分されます。2022年には、モルヒネセグメントが最大の収益シェアで市場を独占しました。モルヒネは、受容体への強固な親和性、安定した性能、豊富なユーザー知識により、髄腔内ドラッグデリバリーの指標となっています。さらに、モルヒネは米国FDAから長期間の髄腔内疼痛治療薬として認可されています。さらに、全身性オピオイドと比較して、長期間の髄腔内モルヒネは副作用が少なく、この市場セグメントの成長を刺激すると予想されます。WHOによれば、モルヒネのようなオピオイドは不快感を緩和する能力が高いため、頻繁に処方されています。オピオイドは、急性疾患から慢性疾患まで、幅広い痛みを効率的に緩和します。オピオイドは、脳や脊髄の特定の受容体に作用することで、痛みのシグナルを減少させる。
地域別展望
地域別に見ると、市場は北米、欧州、アジア太平洋、LAMEAで分析されます。2022年には、北米地域が市場で最も高い収益シェアを記録しました。十分な設備の整った一次、二次、三次医療施設の存在が北米市場の成長を後押ししました。加えて、有利な政府助成金と強固な償還網が市場拡大の原動力になると予想されます。この地域の髄腔内ポンプ需要を刺激すると予想されるのは、主要市場参入企業が製品ラインを強化し、優れた品質を保証するために協力的な取り組みを強めていることです。高度で効果的な髄腔内ポンプに対する需要の高まりは、米国におけるがん罹患率の上昇に起因しています。
The Global Intrathecal Pumps Market size is expected to reach $491.7 million by 2030, rising at a market growth of 5.7% CAGR during the forecast period.
Bupivacaine is regarded as an exceptional adjunctive drug in intrathecal therapy. Thus, the Bupivacaine segment acquired $36,149.5 thousand in 2022. The synergistic enhancement of intrathecal opioid effects when bupivacaine is combined with them has been demonstrated in multiple studies, which has contributed significantly to its expanding market share. Bupivacaine reduces dose escalations of intrathecal opioids and permits some patients to reduce their oral opioid utilization. Thus, it is envisaged that several benefits associated with bupivacaine will sustain segment expansion. Some of the factors impacting the market are technological advancements in pump design, expanding applications in pain management and neurological disorders, and high initial costs and economic considerations.
Modern intrathecal pumps have advanced mechanisms that enable precise and accurate drug delivery. This precision is crucial for administering the proper medication dosage directly to the spinal cord, optimizing therapeutic effects while minimizing the risk of side effects. The integration of smart pump technologies has enhanced the capabilities of intrathecal pumps. These technologies often include remote monitoring, connectivity, and data analytics features. Healthcare providers can remotely monitor patient data, receive real-time alerts, and adjust the pump settings, improving overall patient care and management. Additionally, intrathecal pumps were initially developed for pain management, but their successful application has expanded to address a variety of neurological disorders, including spasticity, dystonia, and severe cases of Parkinson's disease. This diversification broadens the potential patient population benefitting from intrathecal pump therapy. Using these pumps in neurological disorders improves functionality and mobility in affected individuals. By directly targeting the underlying neurological mechanisms, these pumps help reduce muscle spasticity, dystonia, and other symptoms that can enormously impact a person's ability to move and perform daily activities. Healthcare teams comprising pain specialists, neurologists, and other relevant specialists collaborate to develop comprehensive treatment plans that address pain and associated neurological symptoms. Thus, the above-mentioned factors will expand the market growth.
Further, the COVID-19 pandemic moderately impacted the market. Many elective surgeries and medical procedures, including those related to intrathecal pump implantation, were postponed, or canceled during the initial phases of the pandemic. Hospitals and healthcare facilities were under immense pressure to prioritize COVID-19 cases, leading to delays in non-urgent procedures. This delay had influenced the market's growth trajectory, as patients defer elective surgeries, affecting both new installations and replacements. The global disruptions in supply chains caused by the pandemic have affected the availability of medical devices and components. Manufacturers of these pumps and related accessories faced challenges in procuring raw materials, production delays, and logistical issues. These disruptions contributed to fluctuations in the market, affecting both the supply and demand sides. As a result, due to these changes, the market is expected to grow significantly in the coming years.
However, the substantial upfront costs associated with intrathecal pump therapy, including the cost of the pump, surgical implantation, and related procedures, can create financial barriers to access. Patients without adequate insurance coverage or financial resources may face challenges accessing this advanced treatment option. Inconsistent or inadequate reimbursement policies can hinder the widespread adoption of intrathecal pump therapy. The lack of reimbursement or reimbursement rates that do not adequately cover the costs associated with the therapy may discourage healthcare providers from offering it as a treatment option. The financial burden on patients could lead to decreased patient adherence, reluctance to pursue intrathecal pump therapy or potential treatment discontinuation. Due to the above aspects, market growth is expected to decline in the coming years.
Application Outlook
Based on application, the market is fragmented into spasticity and pain. The spasticity segment garnered a significant revenue share in the market in 2022. It delivers medications, such as baclofen, directly to the spinal cord. Baclofen is a muscle relaxant that operates on the central nervous system to reduce spasticity. The targeted delivery allows for a more adequate concentration of the drug at its site of action, leading to better control of muscle tone and spasticity. Controlling spasticity through intrathecal pump therapy can improve muscle function and range of motion. This allows individuals to engage in physical therapy and rehabilitation more effectively, improving overall mobility and functionality.
Type Outlook
On the basis of type, the market is segmented into baclofen, bupivacaine, clonidine, morphine, ziconotide, and others. In 2022, the morphine segment dominated the market with the maximum revenue share. Morphine is the benchmark for intrathecal drug delivery due to its robust affinity for receptors, consistent performance, and substantial body of user knowledge. Furthermore, morphine has been granted sanction by the US FDA for the treatment of long-term intrathecal pain. Furthermore, compared to systemic opioids, long-term intrathecal morphine has fewer adverse effects, which is anticipated to stimulate the growth of this market segment. Owing to their ability to alleviate discomfort, opioids like morphine are frequently prescribed, per the WHO. They efficiently alleviate a wide range of pain, encompassing both acute and chronic ailments. Pain signals are diminished through the action of these medications on specific receptors in the brain and spinal cord.
Regional Outlook
Region-wise, the market is analyzed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the North America region registered the highest revenue share in the market. The presence of adequately equipped primary, secondary, and tertiary care facilities bolstered growth in the North American market. In addition, favorable government funding and a robust reimbursement network are anticipated to drive market expansion. Expected to stimulate demand for intrathecal pumps in this region are the increasing collaborative efforts of key market participants to enhance their product lines and guarantee superior quality. An increased demand for sophisticated and effective intrathecal pumps is a result of the escalating incidence of cancer in the United States.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Medtronic plc, ICU Medical, Inc. (Smiths Medical), Teleflex, Inc., Johnson & Johnson (Johnson & Johnson Services, Inc.), Baxter International, Inc., Abbott Laboratories, Tricumed Medizintechnik GmbH, Flowonix Medical, Inc., Durect Corporation, and Novartis AG
Market Segments covered in the Report:
By Application
By Type
By Geography
Companies Profiled
Unique Offerings from KBV Research